Acadia Pharmaceuticals (ACAD) Assets Average (2011 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Assets Average of $1.6 billion for Q1 2026, up 36.61% year-over-year from $1.2 billion in Q1 2025, and up 9.48% quarter-over-quarter from $1.4 billion in Q4 2025.
Acadia Pharmaceuticals (ACAD) Assets Average (2011 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $1.6 billion for Q1 2026.
- In Q1 2026, Assets Average rose 36.61% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 36.61% YoY), while the FY2025 annual figure was $1.4 billion, up 42.09% from the prior year.
- Assets Average for Q1 2026 stood at $1.6 billion, up from $1.4 billion in the prior quarter.
- The five-year high for Assets Average was $1.6 billion in Q1 2026, with the low at $595.2 million in Q4 2022.
- The 5-year median for Assets Average is $802.0 million (2024), against an average of $908.6 million.
- The sharpest annual moves came in 2022 and 2024: Assets Average decreased 16.4% in 2022, then soared 56.69% in 2024.
- Acadia Pharmaceuticals' Assets Average stood at $595.2 million in 2022, then climbed by 16.06% to $690.7 million in 2023, then jumped by 56.69% to $1.1 billion in 2024, then jumped by 33.74% to $1.4 billion in 2025, then increased by 9.48% to $1.6 billion in 2026.
- Business Quant data shows ACAD's Assets Average at $1.6 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 1.67 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.67 Bn |
| Mar 31, 2026 | 1.58 Bn |
| Dec 31, 2025 | 1.45 Bn |
| Sep 30, 2025 | 1.28 Bn |
| Jun 30, 2025 | 1.18 Bn |
| Mar 31, 2025 | 1.16 Bn |
| Dec 31, 2024 | 1.08 Bn |
| Sep 30, 2024 | 945.48 Mn |
| Jun 30, 2024 | 884.60 Mn |
| Mar 31, 2024 | 802.03 Mn |
| Dec 31, 2023 | 690.75 Mn |
| Sep 30, 2023 | 637.65 Mn |
| Jun 30, 2023 | 649.04 Mn |
| Mar 31, 2023 | 621.56 Mn |
| Dec 31, 2022 | 595.15 Mn |
| Sep 30, 2022 | 607.63 Mn |
| Jun 30, 2022 | 618.51 Mn |
| Mar 31, 2022 | 662.19 Mn |
| Dec 31, 2021 | 708.90 Mn |
| Sep 30, 2021 | 721.05 Mn |